Board of directors (14)
Directors with a Section 16 filing in the last 13 months. “Since” is the first filing as a director; SEC data sets start in 2016.
Executive officers (9)
Company facts
- Chair
- J. David Joyner
- In S&P 500 since
- Mar 1957
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC industry
- Retail-Drug Stores and Proprietary Stores
- SEC filings
- EDGAR
Connections to other S&P 500 companies
Current directors and officers who also hold a role at another S&P 500 company.
Major holders (5% or more)
Latest Schedule 13D/13G filing per holder. Holders that reported falling below 5% are not shown. Index funds usually report once a year.
No 5% holder filings parsed yet for this company.
Insider trades
Open-market purchases and sales reported on Form 4. Grants, option exercises and tax withholding are excluded.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 6, 2026 | Prem S. Shah EVP and Group President | Buy | 23,855 | $83.90 | $2.0M |
| May 21, 2026 | Larry Robbins Director | Sale | 370,462 | $93.45 | $34.6M |
| May 20, 2026 | Larry Robbins Director | Sale | 66,881 | $95.67 | $6.4M |
| May 20, 2026 | Larry Robbins Director | Sale | 800 | $96.28 | $77K |
| May 20, 2026 | Larry Robbins Director | Sale | 797,628 | $93.48 | $74.6M |
| May 20, 2026 | Larry Robbins Director | Sale | 152,691 | $94.81 | $14.5M |
| May 19, 2026 | Larry Robbins Director | Sale | 1,983,387 | $94.45 | $187.3M |
| May 19, 2026 | Larry Robbins Director | Sale | 151 | $95.18 | $14K |
| May 8, 2026 | Tilak Mandadi EVP, Chief Exp & Tech Officer | Sale | 69,551 | $89.58 | $6.2M |
| Aug 20, 2025 | Anne A. Finucane Director | Sale | 7,500 | $71.02 | $533K |
| Jun 5, 2025 | Guy P. Sansone Director | Buy | 1,570 | $63.70 | $100K |
| May 6, 2025 | Larry Robbins Director | Sale | 150,000 | $66.67 | $10.0M |
| May 5, 2025 | Larry Robbins Director | Sale | 96,999 | $67.99 | $6.6M |
| May 5, 2025 | Larry Robbins Director | Sale | 1,226,933 | $67.37 | $82.7M |
| May 2, 2025 | Larry Robbins Director | Sale | 222,556 | $68.38 | $15.2M |
| May 2, 2025 | Larry Robbins Director | Sale | 1,679,736 | $67.39 | $113.2M |
| May 2, 2025 | Larry Robbins Director | Sale | 373,776 | $69.66 | $26.0M |
| Mar 5, 2025 | James David Clark SVP, Cont & Chief Acct Officer | Sale | 7,513 | $66.35 | $498K |
| Feb 18, 2025 | Michael F. Mahoney Director | Buy | 30,000 | $66.70 | $2.0M |
| Jan 23, 2025 | Steven H. Nelson EVP and President, Aetna | Buy | 24 | $53.70 | $1K |
| Oct 23, 2024 | Heidi B. Capozzi EVP and Chief People Officer | Buy | 35 | $56.85 | $2K |
| Oct 2, 2024 | Heidi B. Capozzi EVP and Chief People Officer | Buy | 10 | $62.24 | $622 |
| Sep 9, 2024 | Heidi B. Capozzi EVP and Chief People Officer | Buy | 35 | $56.47 | $2K |
| May 2, 2024 | Edward J. Ludwig Director | Buy | 1,000 | $53.88 | $54K |
| May 2, 2024 | Michael F. Mahoney Director | Buy | 9,181 | $54.49 | $500K |
Board and executive changes
Every 8-K with Item 5.02 (departure, election or appointment of directors and officers). The text is the first paragraph of the item.
- Aug 17, 2026
On August 13, 2026, Larry M. Robbins notified the Board of Directors (the “Board”) of CVS Health Corporation (the “Company”) of his resignation from the Board, effective immediately. Mr. Robbins’ resignation was not the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company. On August 17, 2026, the Board appointed Teresa Heitsenrether to the Board, effective November 18, 2026. Ms. Heitsenrether, age 61, is Executive Vice President and Chief Data & Analytics Officer of JPMorgan Chase & Co. (“JPMorgan Chase”) and is a member of JPMorgan’s Operating Committee. Prior to her current role, Ms. Heitsenrether held several senior leadership positions at JPMorgan Chase, including CEO of Securities Services and Global Head of Prime Brokerage & Equity Financing. She holds an M.B.A. from New York University and a B.S.
Read the 8-K filing - May 18, 2026
(e) On May 14, 2026, CVS Health Corporation (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders approved the 2026 Incentive Compensation Plan of CVS Health Corporation (the “2026 ICP”), which replaces the Company’s expiring 2017 Incentive Compensation Plan. The 2026 ICP applies to awards granted after May 14, 2026. The Management Planning and Development Committee and the Board of Directors of the Company previously approved the 2026 ICP, subject to stockholder approval.
Read the 8-K filing - Mar 19, 2026
(d): On March 18, 2026, the Board of Directors (the “Board”) of CVS Health Corporation (“CVS Health” or the “Company”) elected John E. Gallina to serve on the Board, effective March 19, 2026. Mr. Gallina, age 66, is the former Executive Vice President and Chief Financial Officer (“CFO”) of Elevance Health, Inc. (“Elevance”; NYSE: ELV) a leading health benefits provider. Mr. Gallina served in the CFO role for Elevance from June 2016 through November 1, 2023, then served as EVP and Advisor to the CEO from November 1, 2023 until May 2024, when he retired. During the course of his nearly 30-year career with Elevance, Mr. Gallina held a number of finance and audit-related roles, including Chief Accounting Officer and Chief Risk Officer. Prior to joining Elevance, Mr. Gallina was a senior audit manager and a certified public accountant at Coopers & Lybrand. Mr.
Read the 8-K filing - Apr 8, 2025
Appointment of Brian O. Newman as Executive Vice President and Chief Financial Officer On April 7, 2025, the Board of Directors of CVS Health Corporation (the “Company” or “CVS Health”) appointed Brian O. Newman to serve as Executive Vice President and Chief Financial Officer of CVS Health, effective May 12, 2025 (the “Effective Date”). Mr. Newman will serve as Executive Vice President and Chief Financial Officer Designate of CVS Health from April 21, 2025 until the Effective Date. Mr. Newman, age 56, is currently a member of the Board of Directors of Colgate-Palmolive Company and a member of its Audit Committee and Personnel and Organization Committee. From September 2019 until May 2024, Mr. Newman served as Executive Vice President and Chief Financial Officer of United Parcel Service, Inc. (“UPS”). Prior to joining UPS, Mr.
Read the 8-K filing - Nov 18, 2024
The information set forth in Item 1.01 is incorporated herein by reference. On November 17, 2024, Ms. Norwalk, Mr. Robbins, Mr. Sansone and Mr. Shulman were appointed to the Board. In connection with the appointments of Mr. Robbins, Ms. Norwalk, Mr. Sansone and Mr. Shulman, the size of the Board was increased from 12 to 16 members. Ms. Norwalk was appointed to the HS&T Committee of the Board, Mr. Sansone was appointed to the Audit Committee of the Board and Mr. Shulman was appointed to the Management Planning and Development (“MP&D”) Committee of the Board. Except for the Confidentiality Agreement, there were no arrangements or understandings pursuant to which Ms. Norwalk, Mr. Robbins, Mr. Sansone or Mr. Shulman were appointed to the Board. The Company and its subsidiaries have paid Ms.
Read the 8-K filing - Nov 6, 2024
On November 6, 2024, CVS Health Corporation (the “ Company ”) appointed Prem S. Shah as Executive Vice President and Group President, a newly created position within the Company. As Group President, Mr. Shah will be responsible for the operational performance and integrated value creation from CVS Caremark, CVS Pharmacy, and the Company’s Health Care Delivery businesses, including Oak Street Health and Signify Health. Mr. Shah, age 44, has most recently served as Executive Vice President, Chief Pharmacy Officer and President of Pharmacy & Consumer Wellness, the Company’s retail and pharmacy segment, since January 2023. Previously he served as Executive Vice President and Chief Pharmacy Officer of the Company beginning in November 2022, and as Co-President of Pharmacy & Consumer Wellness from January 2022 until January 2023. From June 2018 until November 2022 Mr.
Read the 8-K filing - Oct 18, 2024
On October 18, 2024, CVS Health Corporation (the “ Company ”) announced that the Board of Directors (the “ Board ”) of the Company appointed J. David Joyner as President and Chief Executive Officer of the Company, effective as of October 17, 2024. Karen S. Lynch ceased to serve as President and Chief Executive Officer of the Company and resigned as a member of the Board on the same day. In connection with Mr. Joyner’s appointment as President and Chief Executive Officer of the Company, the Board appointed Mr. Joyner as a member of the Board and the Executive Committee of the Board. Effective October 17, 2024, the Board has also appointed current Chairman Roger N. Farah as Executive Chairman of the Board. Immediately prior to his appointment as President and Chief Executive Officer, Mr.
Read the 8-K filing - May 22, 2024
(e) On May 16, 2024, CVS Health Corporation (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders approved amendments to the 2017 Incentive Compensation Plan of CVS Health Corporation (the “2017 ICP”), principally to increase the number of common shares of the Company available for issuance under the 2017 ICP by 33.5 million shares. The Management Planning and Development Committee and Board of Directors of the Company previously approved the amendments to the 2017 ICP, subject to stockholder approval.
Read the 8-K filing - Jan 5, 2024
Appointment of Thomas F. Cowhey as Executive Vice President and Chief Financial Officer The Board of Directors (the “Board”) of CVS Health appointed Thomas F. Cowhey to serve as CVS Health’s Executive Vice President and Chief Financial Officer, effective January 5, 2024. Mr. Cowhey has been serving as CVS Health’s interim Chief Financial Officer since October 13, 2023. Mr. Cowhey’s business experience was previously disclosed in
Read the 8-K filing - Oct 16, 2023
Effective October 13, 2023, Shawn M. Guertin, the Executive Vice President and Chief Financial Officer of CVS Health Corporation (“CVS Health,” the “Company,” “we” or “our”), has begun a personal leave of absence for unforeseen family medical reasons. Appointment of Interim Chief Financial Officer In connection with Mr. Guertin’s leave, the Company’s Board of Directors appointed Thomas F. Cowhey, Senior Vice President, Corporate Finance, to serve as the Company’s Interim Chief Financial Officer, effective October 13, 2023. Mr. Cowhey, age 51, had served as our Senior Vice President, Capital Markets since joining the Company in February 2022 and recently expanded his role to include oversight of a broader set of corporate finance functions. Prior to joining CVS Health, Mr.
Read the 8-K filing - Sep 21, 2023
(d): On September 20, 2023, the Board of Directors (the “Board”) of CVS Health Corporation (“CVS Health” or the “Company”) elected Michael F. Mahoney to serve on the Board, effective November 1, 2023. Mr. Mahoney, age 58, has been the President of Boston Scientific Corporation (“Boston Scientific”; NYSE: BSX), a global developer, manufacturer and marketer of medical devices, since October 2011, and has been Chief Executive Officer and a member of the Board of Directors of Boston Scientific since November 2012. He became Chairman of the Board of Directors of Boston Scientific in May 2016. Prior to joining Boston Scientific, Mr. Mahoney s erved as Worldwide Company Group Chairman of Johnson & Johnson’s DePuy franchise, an orthopedics and neurosciences business, from April 2007 through January 2011.
Read the 8-K filing - Jul 20, 2023
(d): On July 19, 2023, the Board of Directors (the “Board”) of CVS Health Corporation (“CVS Health” or the “Company”) elected J. Scott Kirby to serve on the Board, effective October 1, 2023. Mr. Kirby, age 55, has been the Chief Executive Officer and a member of the Board of Directors of United Airlines Holdings, Inc. (“United Airlines”; NYSE: UAL), an international air carrier, since May 2020. Mr. Kirby also serves on the Executive Committee and the Finance Committee of the United Airlines Board of Directors. From August 2016 until May 2020, Mr. Kirby was President of United Airlines and was responsible for its operations, marketing, sales, alliances, network planning and revenue management. Mr. Kirby is a well-known airline industry veteran, with a broad and accomplished three-decade-long career in significant leadership roles.
Read the 8-K filing - Jan 23, 2023
On January 18, 2023, Alan M. Lotvin, M.D., Executive Vice President and President, Pharmacy Services, advised CVS Health Corporation of his intention to retire in April 2023. Section 7 - Regulation FD
Read the 8-K filing - Sep 13, 2022
(d): Effective September 12, 2022, the Board of Directors (the “Board”) of CVS Health Corporation (“CVS Health” or the “Company”) elected Jeffrey R. Balser, M.D., Ph.D., to serve on the Board. Dr. Balser, age 60, serves as President and Chief Executive Officer of Vanderbilt University Medical Center (“VUMC”) and has been its chief executive since 2009. He has also served as Dean of the Vanderbilt University School of Medicine since 2008. VUMC is one of the largest and most prominent academic medical centers in the Southeast, with seven hospitals and 170 outpatient facilities across Tennessee and in neighboring states. As the chief executive of the medical center, Dr.
Read the 8-K filing - Mar 25, 2022
On March 21, 2022, Jonathan C. Roberts, the current Executive Vice President and Chief Operating Officer of CVS Health Corporation (“CVS Health”), informed CVS Health that he intends to retire from CVS Health in June 2022. At this time, CVS Health does not intend to appoint a new Chief Operating Officer. Section 9 – Financial Statements and Exhibits
Read the 8-K filing
Show 15 older changes
- Mar 10, 2022
On March 8, 2022, David W. Dorman, the current Chair of the Board of Directors (the “Board”) of CVS Health Corporation (“CVS Health”), informed the Board that he intends to retire at the end of his current term and will not stand for re-election at the Annual Meeting of Stockholders on May 11, 2022. Mr. Dorman’s retirement is not a result of any disagreement with CVS Health. Mr. Tony L. White, an independent director of the Board of CVS Health, having reached mandatory retirement age, will also retire from the Board effective upon the Annual Meeting of Stockholders. The Board of CVS Health has selected Roger N. Farah, an independent director of the Board and member of the Management Planning and Development and Medical Affairs Committees of the Board, to become Chair of the Board effective May 11, 2022, subject to his re-election at the Annual Meeting of Stockholders. Mr.
Read the 8-K filing - Jun 10, 2021
(e) On May 18, 2021, CVS Health Corporation (“ CVS Health ”, and together with its subsidiaries, the “ Company ”) announced that Eva C. Boratto, former Executive Vice President – Chief Financial Officer of CVS Health, would be stepping down from that role effective May 28, 2021. At the Company’s request to assist in transition and for strategic support, Ms. Boratto has agreed to remain with the Company in a senior advisory role to CVS Health’s President and Chief Executive Officer Karen S. Lynch through no later than December 1, 2021 (such date, the “ Separation Date ”). On June 9, 2021, CVS Pharmacy, Inc., a wholly-owned subsidiary of CVS Health, entered into an agreement (the “ Agreement ”) with Ms. Boratto to memorialize the terms of her continued service and the parties’ mutual agreement to separate. Under the Agreement, the Company has agreed to provide Ms.
Read the 8-K filing - May 18, 2021
Appointment of Shawn M. Guertin as Executive Vice President and Chief Financial Officer On May 17, 2021, the Board of Directors of CVS Health Corporation (“CVS Health”) appointed Shawn M. Guertin, age 57, to serve as Executive Vice President and Chief Financial Officer of CVS Health, effective May 28, 2021 (the “Start Date”). Mr. Guertin is currently a member of the board of directors of DaVita Inc. and TriNet Group, Inc. Mr. Guertin previously served as Executive Vice President, Chief Financial Officer and Chief Enterprise Risk Officer of Aetna Inc. (“Aetna”) from January 2014 to May 2019 and as Senior Vice President, Chief Financial Officer and Chief Enterprise Risk Officer from February 2013 to January 2014.
Read the 8-K filing - Nov 6, 2020
Larry J. Merlo’s Retirement as President and Chief Executive Officer and as a Director On November 6, 2020, CVS Health Corporation (“ CVS Health ”) announced that Larry J. Merlo, currently the President and Chief Executive Officer and a member of the Board of Directors of CVS Health (the “ Board ”), notified CVS Health on November 5, 2020 of his intention to retire effective May 31, 2021 and, in connection therewith, step down from the offices of President and Chief Executive Officer effective February 1, 2021. Thereafter, Mr. Merlo will continue to be employed at CVS Health to assist the new President and Chief Executive Officer on transition matters until his retirement from CVS Health on May 31, 2021. Mr. Merlo has also informed CVS Health that he will not seek re-election to the Board at CVS Health’s 2021 annual meeting of stockholders. In connection with this transition, Mr.
Read the 8-K filing - Mar 6, 2020
(e) On February 12, 2020, CVS Health Corporation (“ CVS Health ”, and together with its subsidiaries, the “ Company ”) announced that Derica W. Rice, former Executive Vice President of CVS Health and President of CVS Caremark, would be leaving CVS Health effective March 1, 2020 (the “ Separation Date ”). In connection with Mr. Rice’s departure, on March 3, 2020, CVS Pharmacy, Inc., a wholly-owned subsidiary of CVS Health, entered into a separation agreement (the “ Separation Agreement ”) with Mr. Rice. Under the Separation Agreement, the Company has agreed to provide Mr. Rice with 18 months of continued base salary as severance following his last day of employment (the “ Severance Period ”). Mr. Rice’s equity awards will vest and be settled in accordance with their existing terms. Specifically, Mr.
Read the 8-K filing - Feb 12, 2020
(b) On February 12, 2020, CVS Health Corporation, a Delaware corporation (“ CVS Health ”), announced that Derica W. Rice, Executive Vice President of CVS Health and President of CVS Caremark, will be leaving CVS Health effective March 1, 2020. Section 9 – Financial Statements and Exhibits
Read the 8-K filing - Feb 7, 2020
(b) As previously disclosed on February 3, 2020, Mark T. Bertolini will not be nominated for re-election to the Board of Directors (the “ Board ”) of CVS Health Corporation (“ CVS Health ”) at the 2020 Annual Meeting of Stockholders. On February 7, 2020, Mr. Bertolini informed the Board of his decision to resign from the Board, effective immediately. Section 9 – Financial Statements and Exhibits
Read the 8-K filing - Feb 3, 2020
Director or officer change (Item 5.02). Open the filing for details.
Read the 8-K filing - Aug 29, 2019
(e) Effective August 28, 2019, the Management Planning and Development Committee of CVS Health Corporation (the “Company”) decided to grant the 2020 performance stock unit (PSU) award to Mr. Larry J. Merlo, our President and Chief Executive Officer. The PSU grant is being awarded at this time to align Mr. Merlo’s incentives to the completion of the Aetna integration and the first phase of the Company’s initiatives to transform health care. This grant is in lieu of Mr. Merlo’s 2020 award and Mr. Merlo will not be granted any PSUs in 2020 (it is expected that he will receive a stock option grant in April 2020 as part of our normal course equity grant practices). The grant date value of the PSU is $10,125,000, which was the target value of Mr. Merlo’s 2019 PSU award.
Read the 8-K filing - Nov 28, 2018
As previously disclosed in the Current Report on Form 8-K filed by CVS Health with the SEC on October 10, 2018, the board of directors of CVS Health (the “Board”) approved an increase in the size of the Board from twelve directors to sixteen directors and appointed Mark T. Bertolini, Edward J. Ludwig, Roger N. Farah and Fernando Aguirre to the Board to fill the resulting vacancies, in each case, effective upon the Effective Time. Effective upon the Effective Time, the Board has appointed Mr. Ludwig as a member of the Audit Committee, Mr. Farah as a member of the Management Planning and Development Committee and the Medical Affairs Committee (formerly known as the Patient Safety and Clinical Quality Committee) and Mr. Aguirre as a member of the Audit Committee and the Nominating and Corporate Governance Committee. In addition, the Board has appointed Mr.
Read the 8-K filing - Nov 20, 2018
Item 7.01 Regulation FD Disclosure. In connection with the closing of the proposed acquisition of Aetna Inc. (the “ Acquisition ”), all of the required change in control filings were submitted to 28 state insurance departments in January 2018. CVS Health Corporation (“ CVS Health ”) has received approval from 26 of the 28 state departments of insurance. CVS Health has made significant progress and is in the final stages of the approval process with the remaining two states. CVS Health is confident that these remaining approvals will be secured. As a result, the Acquisition is now expected to close after the Thanksgiving holiday.
Read the 8-K filing - Oct 22, 2018
Appointment of Chief Accounting Officer On October 22, 2018, CVS Health Corporation (“CVS Health”) announced that its board of directors approved the appointment of James D. Clark as Senior Vice President – Controller and Chief Accounting Officer following the closing of the proposed acquisition of Aetna Inc. (“Aetna”) pursuant to the previously announced Agreement and Plan of Merger, dated as of December 3, 2017, among CVS Health, Aetna and Hudson Merger Sub Corp. (the “Acquisition”). Mr. Clark, age 53, currently Vice President – Finance and Accounting, has been appointed as Senior Vice President – Controller and Chief Accounting Officer of CVS Health effective on the closing date of the Acquisition. Mr. Clark has held his current position at CVS Health since September 2009. Prior to that, Mr. Clark spent 22 years at Deloitte & Touche LLP, including eight years as an audit partner. Mr.
Read the 8-K filing - Oct 10, 2018
Election of Directors Pursuant to the previously announced Agreement and Plan of Merger (the “Merger Agreement”), dated as of December 3, 2017, among CVS Health Corporation (“CVS Health”), Aetna Inc. (“Aetna”) and Hudson Merger Sub Corp., CVS Health and Aetna agreed that, at the completion of CVS Health’s acquisition of Aetna (the “Acquisition”), the size of the board of directors of CVS Health (the “Board”) would be increased by three and the vacancies created thereby would be filled by Mark T. Bertolini, the Chairman and Chief Executive Officer of Aetna, and two other individuals who are serving on the board of directors of Aetna immediately prior to completion of the Acquisition who meet CVS Health’s independence criteria as in effect as of such time and who would be jointly designated by Aetna and CVS Health prior to completion of the Acquisition.
Read the 8-K filing - Jun 6, 2018
(b) and (e) On June 6, 2018, CVS Health Corporation (“ CVS Health ”) announced that David M. Denton, CVS Health’s Executive Vice President and Chief Financial Officer, will be leaving CVS Health at the close of the previously announced acquisition of Aetna Inc. In connection with Mr. Denton’s departure, CVS Health has agreed to provide him 24 months of continued base salary as severance following his last day of employment, as well as subsidized benefits continuation for those 24 months (the “ Severance Period ”). He will receive a pro-rated bonus for calendar year 2018 based on his actual time worked. Mr. Denton’s stock options and restricted stock unit awards (other than his retention restricted stock unit award, which will fully vest on his last day of employment and will be settled in accordance with its terms) will continue to vest through the end of the Severance Period.
Read the 8-K filing - Feb 6, 2018
(b) On February 5, 2018, CVS Health Corporation (the “Registrant”) announced that Helena B. Foulkes, Executive Vice President, CVS Health Corporation and President – CVS Pharmacy, will be leaving employment with the Registrant and its subsidiaries effective February 9, 2018. 2
Read the 8-K filing
Proxy statements (DEF 14A): 2026 · 2025 · 2024 · 2023 · 2022 · 2021
Share price
Annual financials
From the company's 10-K XBRL data (SEC companyfacts).
| Fiscal year | Revenue | Net income | Margin | Diluted EPS | Total assets |
|---|---|---|---|---|---|
| FY2025 | $402.1B | $1.8B | 0.4% | $1.39 | $253.5B |
| FY2024 | $372.8B | $4.6B | 1.2% | $3.66 | $253.2B |
| FY2023 | $357.8B | $8.3B | 2.3% | $6.47 | $249.7B |
| FY2022 | $322.5B | $4.3B | 1.3% | $3.26 | $228.3B |
| FY2021 | $292.1B | $8.0B | 2.7% | $6.02 | $233.0B |
| FY2020 | $268.7B | $7.2B | 2.7% | $5.46 | $230.7B |
| FY2019 | $256.8B | $6.6B | 2.6% | $5.08 | $222.4B |
| FY2018 | $194.6B | -$594.0M | -0.3% | $-0.57 | $216.7B |
Former directors and officers (35)
People who stopped filing as an insider of this company. “Last filing” is the last Form 3/4/5, an upper bound on when they left.